Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
22
SBFM Quote, Financials, Valuation and Earnings
Last price:
$1.44
Seasonality move
:
86.56%
Day range:
$1.41 - $1.48
52-week range:
$1.17 - $3.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.14x
P/B ratio:
0.29x
Volume:
21.2K
Avg. volume:
459.7K
1-year change:
-55.73%
Market cap:
$7M
Revenue:
$34.9M
EPS (TTM):
-$1.86
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SBFM
Sunshine Biopharma, Inc.
|
$11.1M | -- | 4.22% | -- | $6.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $7.00 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SBFM
Sunshine Biopharma, Inc.
|
$1.43 | $6.00 | $7M | -- | $0.00 | 0% | 0.14x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.21 | $0.85 | $152.5M | 2.03x | $0.80 | 0% | 2.35x |
|
NNVC
NanoViricides, Inc.
|
$1.23 | $7.00 | $22.1M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.88 | $2.00 | $727K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.23 | $7.00 | $7.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SBFM
Sunshine Biopharma, Inc.
|
3.41% | 2.230 | 12.57% | 2.02x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SBFM
Sunshine Biopharma, Inc.
|
$3M | -$532K | -23.9% | -24.74% | -5.65% | -$761.9K |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Sunshine Biopharma, Inc. vs. Competitors
-
Which has Higher Returns SBFM or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -9.39% compared to Sunshine Biopharma, Inc.'s net margin of -255.85%. Sunshine Biopharma, Inc.'s return on equity of -24.74% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital SBFMSunshine Biopharma, Inc.31.62% -$0.19 $25.1M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About SBFM or NBY?
Sunshine Biopharma, Inc. has a consensus price target of $6.00, signalling upside risk potential of 319.58%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Sunshine Biopharma, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Sunshine Biopharma, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SBFMSunshine Biopharma, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is SBFM or NBY More Risky?
Sunshine Biopharma, Inc. has a beta of 0.733, which suggesting that the stock is 26.73% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock SBFM or NBY?
Sunshine Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Sunshine Biopharma, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SBFM or NBY?
Sunshine Biopharma, Inc. quarterly revenues are $9.4M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Sunshine Biopharma, Inc.'s net income of -$883.8K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Sunshine Biopharma, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sunshine Biopharma, Inc. is 0.14x versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBFMSunshine Biopharma, Inc.0.14x -- $9.4M -$883.8K NBYNovaBay Pharmaceuticals, Inc.2.35x 2.03x $521K -$1.3M
-
Which has Higher Returns SBFM or NNVC?
NanoViricides, Inc. has a net margin of -9.39% compared to Sunshine Biopharma, Inc.'s net margin of --. Sunshine Biopharma, Inc.'s return on equity of -24.74% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital SBFMSunshine Biopharma, Inc.31.62% -$0.19 $25.1M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About SBFM or NNVC?
Sunshine Biopharma, Inc. has a consensus price target of $6.00, signalling upside risk potential of 319.58%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 469.11%. Given that NanoViricides, Inc. has higher upside potential than Sunshine Biopharma, Inc., analysts believe NanoViricides, Inc. is more attractive than Sunshine Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SBFMSunshine Biopharma, Inc.1 0 0 NNVCNanoViricides, Inc.0 0 0 -
Is SBFM or NNVC More Risky?
Sunshine Biopharma, Inc. has a beta of 0.733, which suggesting that the stock is 26.73% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock SBFM or NNVC?
Sunshine Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sunshine Biopharma, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SBFM or NNVC?
Sunshine Biopharma, Inc. quarterly revenues are $9.4M, which are larger than NanoViricides, Inc. quarterly revenues of --. Sunshine Biopharma, Inc.'s net income of -$883.8K is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, Sunshine Biopharma, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sunshine Biopharma, Inc. is 0.14x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBFMSunshine Biopharma, Inc.0.14x -- $9.4M -$883.8K NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns SBFM or OGEN?
Oragenics, Inc. has a net margin of -9.39% compared to Sunshine Biopharma, Inc.'s net margin of --. Sunshine Biopharma, Inc.'s return on equity of -24.74% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital SBFMSunshine Biopharma, Inc.31.62% -$0.19 $25.1M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About SBFM or OGEN?
Sunshine Biopharma, Inc. has a consensus price target of $6.00, signalling upside risk potential of 319.58%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 126.37%. Given that Sunshine Biopharma, Inc. has higher upside potential than Oragenics, Inc., analysts believe Sunshine Biopharma, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SBFMSunshine Biopharma, Inc.1 0 0 OGENOragenics, Inc.1 0 0 -
Is SBFM or OGEN More Risky?
Sunshine Biopharma, Inc. has a beta of 0.733, which suggesting that the stock is 26.73% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock SBFM or OGEN?
Sunshine Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sunshine Biopharma, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SBFM or OGEN?
Sunshine Biopharma, Inc. quarterly revenues are $9.4M, which are larger than Oragenics, Inc. quarterly revenues of --. Sunshine Biopharma, Inc.'s net income of -$883.8K is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Sunshine Biopharma, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sunshine Biopharma, Inc. is 0.14x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBFMSunshine Biopharma, Inc.0.14x -- $9.4M -$883.8K OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns SBFM or PTN?
Palatin Technologies has a net margin of -9.39% compared to Sunshine Biopharma, Inc.'s net margin of --. Sunshine Biopharma, Inc.'s return on equity of -24.74% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SBFMSunshine Biopharma, Inc.31.62% -$0.19 $25.1M PTNPalatin Technologies-- -- -- -
What do Analysts Say About SBFM or PTN?
Sunshine Biopharma, Inc. has a consensus price target of $6.00, signalling upside risk potential of 319.58%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Sunshine Biopharma, Inc., analysts believe Palatin Technologies is more attractive than Sunshine Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SBFMSunshine Biopharma, Inc.1 0 0 PTNPalatin Technologies0 0 0 -
Is SBFM or PTN More Risky?
Sunshine Biopharma, Inc. has a beta of 0.733, which suggesting that the stock is 26.73% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock SBFM or PTN?
Sunshine Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sunshine Biopharma, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SBFM or PTN?
Sunshine Biopharma, Inc. quarterly revenues are $9.4M, which are larger than Palatin Technologies quarterly revenues of --. Sunshine Biopharma, Inc.'s net income of -$883.8K is higher than Palatin Technologies's net income of --. Notably, Sunshine Biopharma, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sunshine Biopharma, Inc. is 0.14x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBFMSunshine Biopharma, Inc.0.14x -- $9.4M -$883.8K PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns SBFM or TOVX?
Theriva Biologics, Inc. has a net margin of -9.39% compared to Sunshine Biopharma, Inc.'s net margin of --. Sunshine Biopharma, Inc.'s return on equity of -24.74% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital SBFMSunshine Biopharma, Inc.31.62% -$0.19 $25.1M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About SBFM or TOVX?
Sunshine Biopharma, Inc. has a consensus price target of $6.00, signalling upside risk potential of 319.58%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3004.21%. Given that Theriva Biologics, Inc. has higher upside potential than Sunshine Biopharma, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Sunshine Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SBFMSunshine Biopharma, Inc.1 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is SBFM or TOVX More Risky?
Sunshine Biopharma, Inc. has a beta of 0.733, which suggesting that the stock is 26.73% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock SBFM or TOVX?
Sunshine Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sunshine Biopharma, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SBFM or TOVX?
Sunshine Biopharma, Inc. quarterly revenues are $9.4M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Sunshine Biopharma, Inc.'s net income of -$883.8K is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Sunshine Biopharma, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sunshine Biopharma, Inc. is 0.14x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBFMSunshine Biopharma, Inc.0.14x -- $9.4M -$883.8K TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is up 31.68% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 45.78% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.15% over the past day.
